|
Market Closed -
London S.E.
16:35:03 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1500 GBX | +11.11% |
|
+0.33% | -41.18% |
| 09-22 | WINNERS & LOSERS: Petro Matad sinks on PetroChina blow; Midwich up | AN |
| 09-14 | WINNERS & LOSERS: Tribal to sell assets; Brave Bison ups System1 tilt | AN |
| Market Cap | 3.91M 5.19M 4.56M 4.32M 7.35M 498M 7.39M 51.68M 19.96M 254M 19.48M 19.06M 817M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.82M 5.06M 4.45M 4.21M 7.17M 486M 7.21M 50.39M 19.46M 248M 19M 18.59M 796M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | +11.11% | ||
| 1 week | +0.33% | ||
| Current month | -9.09% | ||
| 1 month | -9.09% | ||
| 3 months | -25.00% | ||
| 6 months | -16.67% | ||
| Current year | -41.18% |
| 1 week | 0.13 |  | 0.16 |
| 1 month | 0.13 | | 0.17 |
| Current year | 0.12 | | 0.4 |
| 1 year | 0.12 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 28/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 01/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 31/08/2026 |
Daniel Gooding
BRD | Director/Board Member | 53 | 30/06/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | +0.33% | +3.45% | -46.14% | 4.66M | |
| +0.11% | +1.71% | +63.52% | +117.61% | 1,055B | |
| +0.27% | +0.92% | +51.33% | +73.35% | 654B | |
| +0.73% | +0.68% | +20.70% | +74.90% | 467B | |
| -1.36% | -2.58% | +40.20% | +42.33% | 348B | |
| +1.34% | +4.53% | +23.37% | +29.55% | 275B | |
| -0.48% | -0.54% | +13.56% | +13.50% | 258B | |
| +0.85% | +6.35% | +53.17% | +54.39% | 224B | |
| +0.85% | +1.10% | +35.78% | +101.82% | 187B | |
| -0.30% | -2.98% | -27.62% | -61.28% | 171B | |
| Average | +1.23% | +0.50% | +27.75% | +40.00% | 363.84B | |
| Weighted average by Cap. | -0.05% | +1.00% | +40.69% | +69.85% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.83M -4.25M -4.01M -6.84M -463M -6.88M -48.07M -18.57M -236M -18.12M -17.73M -760M | -653K -865K -761K -719K -1.23M -83.04M -1.23M -8.61M -3.33M -42.38M -3.25M -3.18M -136M |
| Net Debt | -20.21K -26.79K -23.56K -22.28K -37.95K -2.57M -38.18K -267K -103K -1.31M -101K -98.41K -4.22M | -97.55K -129K -114K -108K -183K -12.41M -184K -1.29M -497K -6.33M -486K -475K -20.36M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | GBX 0.1500 | +11.11% | 72,855,027 |
| 25/09/26 | GBX 0.1350 | +4.65% | 1,386,531 |
| 24/09/26 | GBX 0.1290 | -4.44% | 5,712,521 |
| 23/09/26 | GBX 0.1350 | -4.26% | 10,299,283 |
| 22/09/26 | GBX 0.1410 | -5.69% | 5,565,615 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
